Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma - A report of the Children's Cancer Group

Recurrent intracranial ependymoma is rarely cured by surgery, radiotherapy and chemotherapy in conventional doses. This study was designed to determine the toxicity, radiographic response rate and outcome following intensive chemotherapy with ThioTEPA, etoposide, carboplatinum and autologous bone marrow rescue (ABMR) for young children with recurrent central nervous system ependymoma. ThioTEPA 300 mg/m(2)/day (total 900 mg/m(2)) and etoposide 250 to 500 mg/m(2)/day (total 750 to 1500 mg/m(2)) were administered for three consecutive days with or without the addition of carboplatinum 500 mg/m(2)/day (total 1500 mg/m(2)) for an additional three consecutive days, and autologous bone marrow was reinfused 72 hours following chemotherapy. Eligibility criteria required adequate renal, hepatic and pulmonary function, and no tumor infiltration of bone marrow. Fifteen children with recurrent intracranial ependymoma, aged 5 months to 12 years (median 22 months), were treated. Five patients died of treatment related toxicities within 62 days of marrow reinfusion. Eight have expired from progressive disease a median of six months post-ABMR, and one has died from unrelated causes. One child remains alive 25 months post-ABMR, following further disease recurrence. No partial or complete responses were observed. This regimen of high-dose ThioTEPA and etoposide with or without additional carboplatinum with ABMR is not an effective strategy for retrieving heavily pre-treated children with recurrent ependymoma.